Valuation: SpectraCure AB

Market Cap 36.4M 3.77M 3.3M 3.03M 2.83M 5.36M 359M 5.44M 14.15M 177M 14.17M 13.86M 609M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 25.67M 2.66M 2.33M 2.14M 1.99M 3.78M 253M 3.84M 9.98M 125M 9.99M 9.78M 429M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-1.57%
1 week+21.94%
Current month+14.18%
1 month-51.47%
3 months-24.88%
6 months-55.14%
Current year-59.69%
1 week 0.04
Extreme 0.0441
0.08
1 month 0.04
Extreme 0.0403
0.14
Current year 0.04
Extreme 0.0403
0.17
1 year 0.04
Extreme 0.0403
0.32
3 years 0.04
Extreme 0.0403
6.4
5 years 0.04
Extreme 0.0403
13.19
10 years 0.04
Extreme 0.0403
45.15
Manager TitleAgeSince
Chief Executive Officer 54 30/09/2025
Director of Finance/CFO - 31/05/2026
Chief Tech/Sci/R&D Officer - 06/10/2025
Director TitleAgeSince
Director/Board Member 72 31/12/2021
Director/Board Member 63 30/08/2012
Chairman 74 31/12/2021
Date Insider Type Main position Quantity % Market Cap.
25/05/23Buy

Chairman

25,000 0.0257%
29/08/22Buy

Director

25,000 0.0257%
08/07/22Sell

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-1.57%+21.94%-74.57%-98.99% 3.77M
-0.06%+1.87%+53.92%+61.01% 1.6B
+0.76%-0.75%-41.15%-48.65% 296M
-3.57%-0.92%-11.91%-50.91% 54.43M
0.00%+8.33%+23.81%-10.34% 54.12M
Average -0.89%+12.88%-9.98%-29.58% 402.12M
Weighted average by Cap. -0.04%+2.03%+37.11%+39.64%

Financials

2024 2025
Net sales - -
Net income -23M -2.39M -2.09M -1.92M -1.79M -3.39M -227M -3.44M -8.94M -112M -8.95M -8.76M -385M -56.08M -5.81M -5.08M -4.67M -4.35M -8.26M -554M -8.38M -21.8M -272M -21.82M -21.36M -938M
Net Debt -13.13M -1.36M -1.19M -1.09M -1.02M -1.93M -130M -1.96M -5.1M -63.71M -5.11M -5M -220M -10.74M -1.11M -973K -894K -834K -1.58M -106M -1.61M -4.17M -52.1M -4.18M -4.09M -180M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
06/07/26 SEK 0.0628 -1.57% 1,053,494
03/07/26 SEK 0.0638 +10.38% 3,179,269
02/07/26 SEK 0.0578 +1.58% 1,746,018
01/07/26 SEK 0.0569 +3.45% 965,330
30/06/26 SEK 0.0550 +6.80% 8,428,686
  1. Stock Market
  2. Stocks
  3. SPEC Stock